|Bid||234.13 x 1000|
|Ask||234.35 x 1400|
|Day's Range||233.16 - 238.70|
|52 Week Range||107.44 - 242.14|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
AmerisourceBergen's (ABC) Q1 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
Vertex, Intuitive Surgical, Dexcom and Insulet are in buy range ahead of the J.P. Morgan Healthcare Conference. Arrowhead Pharma stock is testing key support.
Dexcom stock is the IBD Stock Of The Day after shares of the diabetes treatment specialist broke out of a flat base to a record high. Dexcom makes devices for patients with diabetes.
Dexcom said Q4 revenue was well above consensus. Gave 2020 revenue guidance that was above views at the midpoint. The glucose monitoring device maker pullback sharply in the morning below a 232.10 entry, but slashed losses.